‘Good progress’ for Tissue Regenix

The York-based company’s expected loss after tax was £2.1m for the first half of 2013, compared with £1.8m in the same period the year before, due to extra development expenditure and increased head count. The company said it had made significant strides in building the group’s US subsidiary, Tissue Regenix Wound Care Inc. It has also signed a processing agreement with Community Tissue Services, one of the US’s largest tissue banks to manufacture DermaPure, Tissue Regenix’s human decellularised dermis product for chronic wounds. The company is also nearing completion of the appointment of distributors across the US.

Antony Odell, Tissue Regenix’s managing director, said: “We have continued to make good progress on the execution of our strategy to commercialise our range of products, and our investments during the first half of the year reflects this plan. We have achieved a number of critical milestones in the past six months and we are focusing on taking the most effective route to open up new international markets for our dCELL products by working with our partners to develop new treatments using our decellularisation technology.”